相关实验视频

Updated: Jul 8, 2025

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

针对CD40和CD40L相互作用的新抑制剂:动脉样硬化治疗的潜力

Kundan Solanki¹, Ashutosh Kumar², Mohd Shahnawaz Khan³

¹Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, Indore, 453552, India.

Current research in structural biology

|December 18, 2023

概括

研究人员设计了针对CD40-CD40L相互作用的新抑制剂,以潜在地治疗动脉样硬化. 这些模仿剂在阻断参与动脉斑块积累的炎症途径方面表现有前途.

科学领域:

心血管研究研究心血管研究
免疫学免疫学免疫学
药物发现药物发现药物发现

背景情况:

动脉样硬化是一种慢性炎症性疾病,由动脉斑块中巨细胞的积累驱动.
单细胞对内皮的招募涉及单细胞上的CD40受体和内皮细胞上的CD40连接体 (CD40L).
抑制CD40-CD40L相互作用是动脉样硬化的潜在治疗策略,但现有的单克隆抗体有并发症.

研究的目的:

设计新的基于的治疗方法,针对动脉样硬化的CD40-CD40L相互作用.
为了确定具有对关键CD40残留物高结合亲和力和有利的安全概况的抑制剂.

主要方法:

利用计算机辅助的药物发现工具和分子对接来设计.
开发和选的二衍生物对CD40结合亲和力,物理化学性质和肝毒性.
进行分子动力学模拟,以评估设计的及其复合物的稳定性.

主要成果:

确定了一种具有高CD40亲和度但也具有阳性肝毒性评分的母.
设计的新型双衍生物具有改善的CD40结合亲和力和负肝毒性.
分子动力学模拟证实了设计的类模拟剂的稳定性.

结论:

设计的双衍生物是向CD40-CD40L相互作用的有希望的候选者.
这些新型疗法可能为减轻动脉样硬化进展提供了一种新的策略.
通过调节单细胞-内皮细胞相互作用,进一步的开发可能会导致动脉样硬化的有效治疗方法.

关键词:

动脉样硬化是一种动脉样硬化.CD40 接收器 CD40 接收器在CD40L中,CD40L是CD40L.在中选.类模拟剂类模拟剂类模拟剂

更多相关视频

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...